Literature DB >> 24474830

Gefitinib, Fluorouracil, Oxaliplatin, and Leucovorin (IFOX) Regimen for Colorectal Cancer.

Alicia S Chen1, Dominic A Solimando1, J Aubrey Waddell1.   

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

Entities:  

Year:  2013        PMID： 24474830      PMCID： PMC3875118          DOI： 10.1310/hpj4811-905

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  29 in total

1.  Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer.

Authors:  Timothy Kuo; Cheryl D Cho; Joanne Halsey; Heather A Wakelee; Ranjana H Advani; James M Ford; George A Fisher; Branimir I Sikic
Journal:  J Clin Oncol       Date:  2005-08-20       Impact factor: 44.544

2.  2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Authors:  Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2006-05-08       Impact factor: 44.544

Review 3.  Antiemetics: American Society of Clinical Oncology clinical practice guideline update.

Authors:  Ethan Basch; Ann Alexis Prestrud; Paul J Hesketh; Mark G Kris; Petra C Feyer; Mark R Somerfield; Maurice Chesney; Rebecca Anne Clark-Snow; Anne Marie Flaherty; Barbara Freundlich; Gary Morrow; Kamakshi V Rao; Rowena N Schwartz; Gary H Lyman
Journal:  J Clin Oncol       Date:  2011-09-26       Impact factor: 44.544

Review 4.  A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer.

Authors:  Keunchil Park; Koichi Goto
Journal:  Curr Med Res Opin       Date:  2006-03       Impact factor: 2.580

Review 5.  Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures.

Authors:  Erick Gamelin; Laurence Gamelin; Laura Bossi; Stefan Quasthoff
Journal:  Semin Oncol       Date:  2002-10       Impact factor: 4.929

6.  Recommended guidelines for the treatment of cancer treatment-induced diarrhea.

Authors:  Al B Benson; Jaffer A Ajani; Robert B Catalano; Constance Engelking; Steven M Kornblau; James A Martenson; Richard McCallum; Edith P Mitchell; Thomas M O'Dorisio; Everett E Vokes; Scott Wadler
Journal:  J Clin Oncol       Date:  2004-07-15       Impact factor: 44.544

7.  Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: a phase I study of the Arbeits gemeinschaft Internistische Onkologie (AIO).

Authors:  Jorg Thomas Hartmann; Jan Peter Pintoffl; Hendrik Kröning; Carsten Bokemeyer; Martin Holtmann; Thomas Höhler
Journal:  Onkologie       Date:  2008-04-10

Review 8.  Hepatotoxicity of chemotherapy.

Authors:  Justin Floyd; Irfan Mirza; Bradley Sachs; Michael C Perry
Journal:  Semin Oncol       Date:  2006-02       Impact factor: 4.929

9.  Hypersensitivity reactions related to oxaliplatin (OHP).

Authors:  G Brandi; M A Pantaleo; C Galli; A Falcone; A Antonuzzo; P Mordenti; M C Di Marco; G Biasco
Journal:  Br J Cancer       Date:  2003-08-04       Impact factor: 7.640

10.  A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation.

Authors:  S Cascinu; R Berardi; S Salvagni; G D Beretta; V Catalano; F Pucci; A Sobrero; P Tagliaferri; R Labianca; M Scartozzi; F Crocicchio; E Mari; A Ardizzoni
Journal:  Br J Cancer       Date:  2007-12-04       Impact factor: 7.640
View more
  1 in total

1.  Gefitinib and Sonidegib.

Authors:  Corey J Medler; J Aubrey Waddell; Dominic A Solimando
Journal:  Hosp Pharm       Date:  2015-11-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.